Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 20/20 | 0.74 |
| ▸ | PDE10A | Q9Y233 | 20/20 | 0.74 |
| ▸ | PDE6D | O43924 | 11/20 | 0.74 |
| ▸ | PDE6A | P16499 | 11/20 | 0.74 |
| ▸ | PDE6G | P18545 | 11/20 | 0.74 |
| ▸ | PDE6B | P35913 | 11/20 | 0.74 |
| ▸ | PDE6C | P51160 | 11/20 | 0.74 |
| ▸ | PDE6H | Q13956 | 11/20 | 0.74 |
| ▸ | PDE4A | P27815 | 3/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.64 |
| ▸ | PDE5A | O76074 | 1/20 | 0.53 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326064 | 0.86 | PDE2A (0.78) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL3325952 | 0.85 | PDE2A (0.72) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL3328245 | 0.85 | PDE2A (1.00) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL3325163 | 0.85 | PDE2A (1.00) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL3325604 | 0.84 | PDE2A (0.74) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL3326032 | 0.84 | PDE2A (0.78) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL3327522 | 0.84 | PDE2A (0.70) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL3324801 | 0.83 | PDE2A (0.72) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL3330721 | 0.82 | PDE2A (0.71) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL3327373 | 0.82 | PDE2A (0.74) | PDE2APDE10APDE6DPDE6APDE6G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | claimed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | PDE2A, PDE5A, PDE3A | PDE2A 1/4885PDE10A 13/4885PDE6D 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.